SFX by Ex Libris Inc.

Title:	Modulation of H+,K+-ATPase activity by the molecular chaperone ERp57 highly expressed in gastric parietal cells
Source:	Febs Letters [0014-5793] Fujii, Takuto yr:2013

Basic

Full text

Full text available via Wiley Online Library Full Collection 2019

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Nagai, T. "The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease." CLINICAL AND EXPERIMENTAL NEPHROLOGY (2017): 884-888.
description	2.	Ishida, K. "Population pharmacokinetics of mizoribine in adult recipients of renal transplantation." Clinical and experimental nephrology (2011): 900-6.
description	3.	Jin, M. "Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation." NATURE COMMUNICATIONS (2021): 6565-6565.
description	4.	Fukao, M. "Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males." DRUG METABOLISM AND PHARMACOKINETICS (2011): 538-543.
description	5.	Hashimoto, Y. "Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells." Biological & pharmaceutical bulletin 33.8 (2010): 1407-745.
description	6.	Nozawa, T. "Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol." Journal of cardiovascular pharmacology 46.5 (2005): 713-20.
description	7.	Kohno, H. "Plasma Concentrations of Tadalafil in Children With Pulmonary Arterial Hypertension." Therapeutic drug monitoring 36.5 (2014): 576-583.
description	8.	Takaai, M. "Contribution of Na+-independent nucleoside transport to ribavirin uptake in the rat intestine and human epithelial LS180 cells." European journal of pharmacology (2008): 61-65.
description	9.	Satomura, K. "Evaluation of limited sampling designs to estimate maximal concentration and area under the curve of mizoribine in pediatric patients with renal disease." drug metabolism and pharmacokinetics (2011): 71-78.
description	10.	Ishida, K. "Variability of bioavailability and intestinal absorption characteristics of bisoprolol." drug metabolism and pharmacokinetics 28.6 (2013): 491-6.
description	11.	Taguchi, M. "Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients." Biological & pharmaceutical bulletin 28.5 (2005): 876-81.
description	12.	Horikiri, Y. "Pharmacokinetics and metabolism of bisoprolol enantiomers in humans." Journal of pharmaceutical sciences 87.3 (1998): 289-94.
description	13.	Fujii, T. "Inhibition of gastric H+,K+-ATPase by new dihydropyrazole derivative KYY-008." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021): 177-182.
description	14.	Taguchi, M. "Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients." European Journal of Clinical Pharmacology 59.5 (2003): 385-388.
description	15.	Horiuchi, I. "Mechanisms responsible for the altered pharmacokinetics of Bosentan: analysis utilizing rats with bile duct ligation‐induced liver dysfunction." Biopharmaceutics & drug disposition 30.6 (2009): 326-333.
description	16.	Fischer, W. "Substrate specificity and mechanism of the intestinal clonidine uptake by Caco-2 cells." Pharmaceutical research 23.1 (2006): 131-137.
description	17.	Horie, A. "Mechanisms for membrane transport of metformin in human intestinal epithelial Caco-2 cells." Biopharmaceutics & drug disposition 32.5 (2011): 253-260.
description	18.	Rehak, E. "Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol." European journal of clinical pharmacology (1998): 469-474.
description	19.	Okita, K. "A more efficient method to generate integration-free human iPS cells." Nature Methods 8.5 (2011): 409-12.
description	20.	Guchelaar, G A P J M A. "Pharmacogenetics: From Bench to Byte- An Update of Guidelines." Clinical pharmacology & therapeutics 89.5 (2011): 662-73.